Amubarvimab, previously known as BRII-196 , represents a significant advancement in antibody development, particularly concerning its capacity to block COVID-19. This engineered antibody demonstrates https://socialmediainuk.com/story27044541/amubarvimab-a-deep-analysis-into-brii-196-s-prospects